SG11202009439YA - Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same - Google Patents

Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Info

Publication number
SG11202009439YA
SG11202009439YA SG11202009439YA SG11202009439YA SG11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA
Authority
SG
Singapore
Prior art keywords
grow
live
same
vaccine composition
fever virus
Prior art date
Application number
SG11202009439YA
Other languages
English (en)
Inventor
Manuel Vangelisti
Nathalie Mantel
Yves Girerd-Chambaz
Fabienne Piras
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG11202009439YA publication Critical patent/SG11202009439YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/08Inactivation or attenuation by serial passage of virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24164Methods of inactivation or attenuation by serial passage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009439YA 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same SG11202009439YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305405.5A EP3549603A1 (en) 2018-04-06 2018-04-06 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
PCT/EP2019/058268 WO2019192997A1 (en) 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Publications (1)

Publication Number Publication Date
SG11202009439YA true SG11202009439YA (en) 2020-10-29

Family

ID=62046805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009439YA SG11202009439YA (en) 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Country Status (15)

Country Link
US (2) US11471521B2 (es)
EP (2) EP3549603A1 (es)
JP (1) JP7370338B2 (es)
KR (1) KR20200140292A (es)
CN (1) CN111918669A (es)
AR (1) AR114471A1 (es)
AU (1) AU2019249329A1 (es)
BR (1) BR112020018879A2 (es)
CA (1) CA3095438A1 (es)
CO (1) CO2020011984A2 (es)
PE (1) PE20210317A1 (es)
SG (1) SG11202009439YA (es)
TW (1) TWI835787B (es)
WO (1) WO2019192997A1 (es)
ZA (1) ZA202006280B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549603A1 (en) * 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
DK2459709T3 (en) * 2009-07-31 2014-12-01 Ge Healthcare Bio Sciences HIGH-REPLACED YELLOW FEBER VIRUS TREASURY WITH INCREASED CELL STORAGE
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
EP3549603A1 (en) * 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Also Published As

Publication number Publication date
BR112020018879A2 (pt) 2021-01-26
US20210154289A1 (en) 2021-05-27
KR20200140292A (ko) 2020-12-15
US11452772B2 (en) 2022-09-27
AR114471A1 (es) 2020-09-09
WO2019192997A1 (en) 2019-10-10
US20220047692A1 (en) 2022-02-17
PE20210317A1 (es) 2021-02-16
TW202003028A (zh) 2020-01-16
TWI835787B (zh) 2024-03-21
RU2020136260A (ru) 2022-05-06
ZA202006280B (en) 2022-06-29
US11471521B2 (en) 2022-10-18
CA3095438A1 (en) 2019-10-10
JP7370338B2 (ja) 2023-10-27
AU2019249329A1 (en) 2020-12-03
EP3549603A1 (en) 2019-10-09
CN111918669A (zh) 2020-11-10
EP3773701A1 (en) 2021-02-17
CO2020011984A2 (es) 2021-02-08
JP2021520384A (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
IL263373A (en) Genetically modified vaccinia virus, preparations containing it and its uses
HK1257074A1 (zh) 溶瘤病毒株
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
DK3310909T3 (da) Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet
HK1255192A1 (zh) 表達細胞因子和羧酸酯酶的修飾的溶瘤痘苗病毒及其使用方法
EP3207051A4 (en) Copi coatomer alpha subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
JO3765B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18 (18hpv)
EP3206495A4 (en) Copi coatomer delta subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
SG10201913600RA (en) Adoptive cell transfer and oncolytic virus combination therapy
EP3305310A4 (en) ONCOLYTIC VIRUS FORMULATION AND MANUFACTURING METHOD THEREFOR
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP3518947C0 (en) OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF
MA42845A (fr) Souches vaccinales de listeria de recombinaison et méthodes d'utilisation desdites souches dans l'immunothérapie anticancéreuse
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
SG11202106394PA (en) Adaptation of enterovirus to vero cells and vaccine formulations thereof
ZA202000574B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
HK1253377A1 (zh) 可編程的溶瘤病毒疫苗系統及其應用
HK1219500A1 (zh) 遺傳穩定的溶瘤性 病毒、其製備方法及用途
EP3515483A4 (en) HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
HK1255379A1 (zh) 丙型肝炎病毒免疫原性組合物及其使用方法
EP3664846A4 (en) ANTIBODIES AGAINST THE EPSTEIN-BARR VIRUS AND ITS USES
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.